Biology:Velaglucerase alfa
| Clinical data | |
|---|---|
| Trade names | Vpriv |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Elimination half-life | Plasma: 5–12 minutes (absorbed by macrophages) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C2532H3850N672O711S16 |
| Molar mass | 55593.61 g·mol−1 |
  (what is this?) (verify) | |
Velaglucerase alfa, sold under the brand name Vpriv, is a medication used for the treatment of Gaucher disease Type 1.[1] It is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase. It has an identical amino acid sequence to the naturally occurring enzyme.[2] It is manufactured by Shire plc.
The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.[3]
Velaglucerase alfa was approved for medical use in the United States in February 2010,[4][5] and in the European Union in August 2010.[3]
Medical uses
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease.[3][1]
References
- ↑ 1.0 1.1 1.2 "Vpriv- velaglucerase alfa injection, powder, lyophilized, for solution". 18 June 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ca02f7a4-ae4f-43c1-a06a-259fe4fcf9cf.
- ↑ "Velaglucerase alfa in the treatment of Gaucher disease type 1". Clinical Investigation 1 (2): 285–293. February 2011. doi:10.4155/cli.10.21. PMID 21927713.
- ↑ 3.0 3.1 3.2 "Vpriv EPAR". 17 September 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Shire Announces FDA Approval Of Vpriv (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease". Medical News Today. 27 February 2010. http://www.medicalnewstoday.com/articles/180630.php.
- ↑ "Drug Approval Package: Vpriv (Velaglucerase alfa) NDA #022575". 24 February 2010. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022575s000TOC.cfm.
External links
- "Velaglucerase alfa". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/velaglucerase%20alfa.
 |  |
